Skip to content
OpenCapital
Get started

Prestige Consumer Healthcare PBH Dermatologicals — Total revenues

Other product segments

Gastrointestinal
$68.35M-0.8%
Women's Health
$57.05M-10.6%
Eye & Ear Care
$37.85M-19.0%
Analgesics
$28.24M-6.5%
Oral Care
$28M+3.3%
Cough & Cold
$26.29M-2.3%
Other OTC
$5.35M+39.2%

Similar metrics at other companies

Zoetis logo
ZTSDermatology — Revenue
$349M-7.9%
Arcutis Biotherapeutics, Inc. logo
ARQTReportable Segment — Total revenues
$105.4M+60.1%
Gentex logo
GNTXMedical Products — Total Revenue
$353.62K-8.6%
Bausch + Lomb logo
BLCOPharmaceuticals — Total revenues
$266M+19.8%
Amneal Pharmaceuticals, Inc. logo
AMRXTransdermal — Net revenue
$73.96M+71.8%
Bausch + Lomb logo
BLCODevices — Total revenues
$480M+7.1%

Other financials

Income statement

See full
Revenue$281.6M-5.0%
Gross profit$146.3M-13.9%
Operating income$75.5M-14.6%
Net income$53.9M+7.6%
EPS (diluted)$1.13+11.9%

Balance sheet

See full
Cash & equivalents$63.9M-34.8%
Total debt$1.0B-0.2%
Total equity$1.9B+2.9%
Total assets$3.5B+2.7%

Cash flow

See full
Operating cash flow$42.8M-30.7%
CapEx$5.2M+49.8%
Free cash flow$37.6M-35.5%

Valuation

See full
Market cap$2.18B-34.1%
Enterprise value$3.16B-27.3%
P/E11.5×-4.0×
P/S2×-0.9×

Profitability

See full
Gross margin54.7%-1.1pp
Operating margin28.4%-1.2pp
Net margin17.5%-1.4pp
FCF margin22.6%+1.3pp

Returns & leverage

See full
Return on equity10.2%-2.1pp
Debt / equity0.6×0.0×
Current ratio3.6×-0.6×

Where this comes from

Reported directly by Prestige Consumer Healthcare in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Prestige Consumer Healthcare’s 10-K, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Prestige Consumer Healthcare's dermatologicals — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Prestige Consumer Healthcare's dermatologicals — total revenues?
Prestige Consumer Healthcare (PBH) reported dermatologicals — total revenues of $30.49M in Q1 2026.
How has Prestige Consumer Healthcare's dermatologicals — total revenues changed year-over-year?
Prestige Consumer Healthcare's dermatologicals — total revenues increased by 4.8% year-over-year, from $29.08M to $30.49M.
What is the long-term trend for Prestige Consumer Healthcare's dermatologicals — total revenues?
Over 4 years (2022 to 2026), Prestige Consumer Healthcare's dermatologicals — total revenues has grown at a 1.1% compound annual growth rate (CAGR), from $120.39M to $125.93M.
What does dermatologicals — total revenues mean?
This metric represents the total gross sales generated from the company's portfolio of dermatological and skin-related healthcare products. It reflects the market demand and commercial performance of these specific over-the-counter health offerings within the broader consumer healthcare segment. Tracking this revenue stream helps investors assess the growth trajectory and competitive positioning of the firm's specialized skin health category.